Swissmedic-Regulated GLP Toxicology Studies for Next-Generation Engineered AAV Capsids

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Swissmedic-Regulated GLP Toxicology Studies for Next-Generation Engineered AAV Capsids

Swissmedic-Regulated GLP Toxicology for Engineered AAV Capsids

CELL & GENE | RNA | BIOLOGICS

  • De-risking Novel Capsid Biology for European Clinical Translation.*

    • How do Swissmedic GLP requirements for AAV toxicology differ from FDA/EMA?

    While harmonized under ICH guidelines, Swissmedic places specific emphasis on detailed documentation of vector manufacturing consistency and robust justification for the selected animal model. Our programs are designed with a global submission mindset, generating a core data package that meets FDA, EMA, and Swissmedic requirements, with specific addenda and report formats tailored for Swissmedic review.

    What are the key toxicology endpoints for an engineered AAV capsid study?

    Beyond standard toxicology assessments, key endpoints for engineered capsids include comprehensive non-target tissue biodistribution via qPCR or ddPCR, rigorous immunogenicity profiling (including anti-capsid NAb assays), and detailed histology of tissues predicted by the capsid’s engineered tropism. We also evaluate potential off-target expression of the transgene payload.

    How do you manage potential immunogenicity from novel capsids in GLP studies?

    Our approach involves a multi-faceted immunotoxicity assessment. This includes baseline screening for pre-existing neutralizing antibodies in the study population and in-life monitoring of both humoral (binding and neutralizing antibodies) and cellular (e.g., ELISpot) immune responses to the novel capsid proteins throughout the study duration.

    What is the typical study duration for a definitive AAV toxicology program?

    The in-life phase for a definitive non-rodent toxicology study typically ranges from 6 to 12 months, depending on the therapeutic indication and transgene biology. The complete program, from protocol finalization to final report delivery, aligns with our standard 18-24 month timeline to support an Investigational New Drug (IND) or Clinical Trial Authorisation (CTA) submission.

To secure Swissmedic approval for gene therapies utilizing engineered adeno-associated virus (AAV) capsids, sponsors must execute GLP-compliant toxicology studies that rigorously characterize the safety profile of the novel vector. This requires a deep understanding of how capsid modifications alter tissue tropism, biodistribution, and immunogenicity. Franklin Biolabs provides comprehensive, Swissmedic-aligned toxicology programs that integrate vector biology with regulatory science, generating the definitive safety data required for clinical translation in Switzerland and globally.

Characterizing Novel Capsid Biodistribution and Safety

Engineered AAV capsids are designed to enhance tissue specificity and overcome pre-existing immunity, but these modifications demand a bespoke toxicology evaluation. A primary regulatory concern is confirming that the engineered tropism does not result in unintended toxicity in non-target tissues. A comprehensive non-target tissue biodistribution study is a primary component of the safety program.

Scientific literature demonstrates the necessity of this empirical approach. For instance, comparative analyses show that engineered capsids can exhibit transduction efficiencies and liver-targeting capabilities distinct from natural serotypes (PMID: 26412589). This variability underscores that safety data cannot be extrapolated from parent serotypes; each new capsid requires a full toxicological assessment. Our >100,000 sq ft GxP-compliant facility is equipped to conduct these large-scale biodistribution and safety studies.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Navigating Immunogenicity of Next-Generation Vectors

A key challenge for next-generation AAV vectors is the potential for inducing an immune response to the novel capsid proteins. While capsid engineering aims to evade pre-existing neutralizing antibodies, the new protein sequences can present novel epitopes. Research into mapping neutralizing epitopes shows that while single mutations can reduce antibody binding, a broader strategy is often required to fully evade a polyclonal immune response (PMID: 30089698).

This biological reality necessitates a robust immunotoxicity assessment within the GLP toxicology program. Our study designs incorporate comprehensive evaluations of both humoral and cellular immune responses to the capsid.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

GLP Compliance and Animal Welfare for Swissmedic

Executing studies to meet Swissmedic standards requires unwavering adherence to GLP principles and the highest standards of animal welfare. Our programs are designed to generate data packages that support a typical 18-24 month IND or CTA timeline. Since 2019, programs run by our scientific leadership have achieved a 100% IND success rate (the Franklin Biolabs brand itself launched in 2024).

Our commitment to responsible research is fundamental to our operations.

Our animal welfare program is managed in strict accordance with AAALAC and USDA guidelines, fully integrating the principles of the 3Rs (Reduction, Refinement, and Replacement) into every study protocol.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities